Stem definition | Drug id | CAS RN |
---|---|---|
5201 | 906673-24-3 |
None
None
Date | Agency | Company | Orphan |
---|---|---|---|
March 27, 2020 | EMA | Pfizer Europe MA EEIG | |
Dec. 14, 2016 | FDA | ANACOR PHARMS INC |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Application site pain | 2144.54 | 95.96 | 332 | 2276 | 3851 | 53342607 |
Burning sensation | 712.66 | 95.96 | 203 | 2405 | 47810 | 53298648 |
Application site erythema | 253.60 | 95.96 | 57 | 2551 | 5034 | 53341424 |
Dermatitis atopic | 169.66 | 95.96 | 39 | 2569 | 3795 | 53342663 |
Drug ineffective | 165.50 | 95.96 | 199 | 2409 | 817046 | 52529412 |
Application site pruritus | 140.56 | 95.96 | 34 | 2574 | 4115 | 53342343 |
Drug effective for unapproved indication | 124.60 | 95.96 | 27 | 2581 | 2003 | 53344455 |
Skin burning sensation | 118.38 | 95.96 | 37 | 2571 | 11573 | 53334885 |
Application site swelling | 111.49 | 95.96 | 20 | 2588 | 554 | 53345904 |
Eczema | 98.81 | 95.96 | 39 | 2569 | 24143 | 53322315 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Application site pain | 1134.63 | 161.95 | 163 | 962 | 1611 | 32510790 |
Burning sensation | 400.39 | 161.95 | 97 | 1028 | 17381 | 32495020 |
Application site erythema | 171.92 | 161.95 | 34 | 1091 | 2309 | 32510092 |
Source | Code | Description |
---|---|---|
ATC | D11AH06 | DERMATOLOGICALS OTHER DERMATOLOGICAL PREPARATIONS OTHER DERMATOLOGICAL PREPARATIONS Agents for dermatitis, excluding corticosteroids |
FDA MoA | N0000182960 | Phosphodiesterase 4 Inhibitors |
FDA EPC | N0000182961 | Phosphodiesterase 4 Inhibitor |
CHEBI has role | CHEBI:35475 | non-steroidal anti-inflammatory drugs |
CHEBI has role | CHEBI:50748 | antipsoriatic agent |
CHEBI has role | CHEBI:68844 | PDE4 inhibitors |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Atopic dermatitis | indication | 24079001 | DOID:3310 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 7.8 | acidic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
2% | EUCRISA | ANACOR PHARMS INC | N207695 | Dec. 14, 2016 | RX | OINTMENT | TOPICAL | 8501712 | Feb. 16, 2027 | METHOD OF TREATING MILD TO MODERATE ATOPIC DERMATITIS. |
2% | EUCRISA | ANACOR PHARMS INC | N207695 | Dec. 14, 2016 | RX | OINTMENT | TOPICAL | 9682092 | Feb. 16, 2027 | METHOD OF TREATING MILD TO MODERATE ATOPIC DERMATITIS. |
2% | EUCRISA | ANACOR PHARMS INC | N207695 | Dec. 14, 2016 | RX | OINTMENT | TOPICAL | 8168614 | Jan. 20, 2030 | METHOD OF TREATING MILD TO MODERATE ATOPIC DERMATITIS. |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
2% | EUCRISA | ANACOR PHARMS INC | N207695 | Dec. 14, 2016 | RX | OINTMENT | TOPICAL | June 14, 2022 | PEDIATRIC EXCLUSIVITY |
2% | EUCRISA | ANACOR PHARMS INC | N207695 | Dec. 14, 2016 | RX | OINTMENT | TOPICAL | March 23, 2023 | NEW PATIENT POPULATION |
2% | EUCRISA | ANACOR PHARMS INC | N207695 | Dec. 14, 2016 | RX | OINTMENT | TOPICAL | Sept. 23, 2023 | PEDIATRIC EXCLUSIVITY |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Phosphodiesterase 4 | Enzyme | INHIBITOR | IC50 | 6.31 | SCIENTIFIC LITERATURE | DRUG LABEL | |||
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A | Enzyme | IC50 | 5.21 | CHEMBL | |||||
High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A | Enzyme | IC50 | 6.14 | CHEMBL |
ID | Source |
---|---|
Q2R47HGR7P | UNII |
4036360 | VANDF |
C4301781 | UMLSCUI |
CHEBI:134677 | CHEBI |
CHEMBL484785 | ChEMBL_ID |
44591583 | PUBCHEM_CID |
DB05219 | DRUGBANK_ID |
D10873 | KEGG_DRUG |
C543085 | MESH_SUPPLEMENTAL_RECORD_UI |
9151 | IUPHAR_LIGAND_ID |
10024 | INN_ID |
1865953 | RXNORM |
248463 | MMSL |
32196 | MMSL |
017053 | NDDF |
724007009 | SNOMEDCT_US |
763593001 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Staquis | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0009-2211 | OINTMENT | 20 mg | TOPICAL | EXPORT ONLY | 1 sections |
Eucrisa | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55724-211 | OINTMENT | 20 mg | TOPICAL | NDA | 27 sections |